Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

Makoto Nishio(Japanese Foundation For Cancer Research), Koichi Azuma(Kyushu University Hospital), Hisato Kawakami(Tohoku University), Shuji Murakami(Kanagawa Cancer Center), Taro Semba(Eisai (Japan)), Daiko Matsuoka(Eisai (Japan)), Takao Takase(Eisai (Japan)), Noboru Yamamoto(Tokyo National Hospital), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Yuko Oya(Fujita Health University Hospital), Motohiro Tamiya(Osaka International Cancer Institute), Haruki Kobayashi(Shizuoka Cancer Center), Toshiyuki Kozuki(Shikoku Cancer Center), Yohei Otake(Eisai (Japan)), Shunichi Sugawara(Sendai Kousei Hospital), Daichi Fujimoto(Hyogo University), Takayuki Shiroyama(Osaka City University), Kyoichi Okishio(NHO Kinki Chuo Chest Medical Center), Shota Kaname(Ono Pharmaceutical (Japan)), Hiroki Izumi(National Cancer Center Hospital East)
Cancer Research Communications
January 5, 2024
10.1158/2767-9764.crc-23-0313
Cited by 4

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
|The Lancet Respiratory Medicine|2019|937